Home/Get Matched/NCT07024628
Recruiting
View on ClinicalTrials.gov

Comparing Heat adaptation digital messaging with Non-heat-related digital messaging for heathly subjects

Official title: Assessing the Effectiveness of Heat Adaptation Digital Messages From Primary Care Providers to Their Patients on the Change in Behaviour for Heatwave-related Preparedness

Heat Smart: Empowering Primary Care Providers to Safeguard Vulnerable Populations Against Extreme Heat

Condition: Heathly SubjectsSponsor: Hopital MontfortTarget enrollment: 20000
  • 2 groups
  • One site, in Ottawa
  • Recruiting
Institut du Savoir Montfort, Ottawa, Ontario

Interventions

  • Other intervention

    Heat adaptation digital messaging

    Digital messages to equip and prepare patients for extreme heat events. The first message will to encourage patients to prepare by creating a heat safety plan, and to form Check-in Companion groups among friends, neighbours, and relatives as well as to connect patients with existing key infrastructure that can be vital during heat events (ex: cooling stations and public facilities with air conditioning). When a heat-advisory is announced, additional messages will be sent to alert patients in the Treated group to activate their heat safety plans.

  • Other intervention

    Non-heat-related digital messaging

    Digital health promotion messages not related to heatwaves

Canadian Sites (1)

1 of 1 recruiting

  • Institut du Savoir Montfort

    Ottawa, Ontario

    Recruiting

Eligibility Criteria

See who this study is looking for18 criteria

The trial’s own eligibility text, word for word from the registry. Only the trial site can say who takes part.

Inclusion

  • +The Heat Smart randomizedRandomisedWhich group you go into is decided by chance, not by you or your doctor.Read more → controlled trial study will recruit patients and primary care providers (PCPs) from Eastern Ontario. The inclusion criteriaInclusion criteriaThe things you must have or be for a study to consider you.Read more → ensure that the intervention reaches at-risk individuals while being scalable across different patient populations:
  • +Primary Care Patients:
  • +Adults (18 years and older)
  • +Patients must be registered with a participating PCP.
  • +They must have had at least one visit with their PCP in the past two years to ensure active engagement.
  • +Participants must have an active email, cell phone or messaging service (SMS) to receive Heat Smart digital messages.
  • +Patients must be able to understand and consentInformed consentThe process of being told what taking part involves, then choosing freely.Read more → to participate in the study.
  • +Patients must be able to communicate in at least one of the official languages (English, French).
  • +Participants will be recruited from PCP located in two Eastern Ontario public health districts: the Eastern Ontario Health Unit and Ottawa Public Health (including urban, rural, and Indigenous communities such as Akwesasne).
  • +Primary Care Providers:
  • +Must be a licensed Family Physician (FP) or Nurse Practitioner (NP) in a practice of at least 2 PCPS.
  • +The providers must be offering comprehensive primary care to a panel of patients (not solely urgent care or walk-in services).
  • +Must work in a computerized primary care clinic with an electronic medical record system.
  • +Must expect to remain in practice for at least 24 months.
  • +Must be located in Eastern Ontario.
  • +Must be willing to use the Canadian Primary Care Information Network (CPIN) to deliver Heat Smart messages and surveys.
  • +Must be using Cliniconex or Qualtrics as a practice tool for communication enabling outreach before the patients are invited to consent to participate in the study.

Exclusion

  • Patients who do not read French or English will be excluded from the study as they will not be able to give informed consentInformed consentThe process of being told what taking part involves, then choosing freely.Read more → or to fill out the surveys. Patients who do not have an email address or text messaging service will be excluded for the same reason. Minors, patients with dementia and people who cannot read and write in English or French will not be eligible because the automated approach to surveying patients makes it impractical to properly obtain their consent.
5 concepts to explore on this page · up to 1,300 pointsTap any term to learn what it means.

In plain language

Assembled directly from this trial’s registry record. Every sentence traces to a field below — nothing here is generated or interpreted.

Learning 
What this study is

This study is testing a way to prevent a condition from developing.

This study is not organised into the usual phase numbers — that is common for device, behavioural, and diagnostic research.

From the trial registry

Built from these fields:

  • designModule.designInfo.primaryPurpose
  • designModule.phases
Who receives what

There are 2 groups in this study.

Group A receives Heat adaptation digital messaging.

Registry label: A: Treated - receive heat adaptation digital messages

Group B, the comparison group, receives Non-heat-related digital messaging.

Registry label: B: Control

From the trial registry

Built from these fields:

  • armsInterventionsModule.armGroups[].label
  • armsInterventionsModule.armGroups[].type
  • armsInterventionsModule.armGroups[].interventionNames
How the study is run

Which group you would be placed in is decided by chance, like a coin flip — not by you and not by your doctor.

You, the study team, the people giving the treatment, and the people analysing the results would all be kept unaware of which group you are in until the study ends.

From the trial registry

Built from these fields:

  • designModule.designInfo.allocation
  • designModule.designInfo.maskingInfo.masking
Is there a placebo?

This study does not list a placeboPlaceboA dummy treatment with no active medicine, used for comparison.Read more → group.

One group receives an existing treatment, so the two can be compared.

From the trial registry

Built from these fields:

  • armsInterventionsModule.armGroups[].type
  • armsInterventionsModule.armGroups[].interventionNames
Who the study is looking for

The study lists a minimum age of 18 years, with no upper limit given.

The study is open to people of any sex.

The study accepts healthy volunteersHealthy volunteerSomeone without the condition being studied who takes part anyway.Read more → as well as people with the condition.

These are the criteria the study lists. Only the trial siteTrial siteA hospital or clinic where a study is actually run.Read more → can decide whether someone can take part.

From the trial registry

Built from these fields:

  • eligibilityModule.minimumAge
  • eligibilityModule.sex
  • eligibilityModule.healthyVolunteers
How big and how long

The study aims to enrol about 20,000 people.

The study is currently expected to finish around March 2028.

The main measurement is taken over: Assessed after a heatwave event, up to 2 years following enrollmentEnrolmentThe number of participants a study plans to include, or has included.Read more →.

From the trial registry

Built from these fields:

  • designModule.enrollmentInfo.count
  • statusModule.completionDateStruct.date
  • outcomesModule.primaryOutcomes[].timeFrame
What the study measures

Number of participants who report adopting at least one heat adaptation behaviour via self-report survey — measured over Assessed after a heatwave event, up to 2 years following enrollmentEnrolmentThe number of participants a study plans to include, or has included.Read more →.

From the trial registry

Built from these fields:

  • outcomesModule.primaryOutcomes[].measure
  • outcomesModule.primaryOutcomes[].timeFrame

Source: NCT07024628 on ClinicalTrials.gov. The full registry text is further down this page — this summary never replaces it.

Not medical advice. What do these terms mean?

What is being tested — in plain terms

About Heat adaptation digital messagingOther

Digital messages to equip and prepare patients for extreme heat events. The first message will to encourage patients to prepare by creating a heat safety plan, and to form Check-in Companion groups among friends, neighbours, and relatives as well as to connect patients with existing key infrastructure that can be vital during heat events (ex: cooling stations and public facilities with air conditioning). When a heat-advisory is announced, additional messages will be sent to alert patients in the Treated group to activate their heat safety plans.

From the trial registry — its own words, unedited.

What a other is here: An intervention the registry did not place in another category.

Read the full explanation → · in clinical review

About Non-heat-related digital messagingOther

Digital health promotion messages not related to heatwaves

From the trial registry — its own words, unedited.

What a other is here: An intervention the registry did not place in another category.

Read the full explanation → · in clinical review

Common questions

Answered from this trial’s registry record. Where the record doesn’t say, these answers say so rather than filling the gap.

Am I eligible for this trial?

Only the trial siteTrial siteA hospital or clinic where a study is actually run.Read more → can decide whether someone can take part. Concord cannot make that determination, and neither can any tool that has not examined you.

What the study lists: a minimum age of 18 years.

The full inclusionInclusion criteriaThe things you must have or be for a study to consider you.Read more → and exclusion criteriaExclusion criteriaThe things that would prevent someone from taking part.Read more → are published on this page, exactly as the study team wrote them.

The useful next step is to bring this trial to your doctor. Answering a few questions first gives them something concrete to review.

From the trial registry
  • eligibilityModule.minimumAge
  • eligibilityModule.eligibilityCriteria
Is there a placebo?

This study does not list a placeboPlaceboA dummy treatment with no active medicine, used for comparison.Read more → group.

One group receives an existing treatment so the two can be compared.

From the trial registry
  • armsInterventionsModule.armGroups[].type
Would I know which treatment I am getting?

You, the study team, the people giving the treatment, and the people analysing the results would all be kept unaware of which group you are in until the study ends.

Which group you would be placed in is decided by chance, like a coin flip — not by you and not by your doctor.

From the trial registry
  • designModule.designInfo.maskingInfo.masking
  • designModule.designInfo.allocation
Who can join?

The study lists a minimum age of 18 years, with no upper limit given.

It is open to people of any sex.

It accepts healthy volunteersHealthy volunteerSomeone without the condition being studied who takes part anyway.Read more → as well as people with the condition.

Only the trial siteTrial siteA hospital or clinic where a study is actually run.Read more → can confirm whether a particular person can take part.

From the trial registry
  • eligibilityModule.minimumAge
  • eligibilityModule.sex
  • eligibilityModule.healthyVolunteers
How long would this take?

The study's main measurement is taken over: Assessed after a heatwave event, up to 2 years following enrollmentEnrolmentThe number of participants a study plans to include, or has included.Read more →..

The study as a whole is currently expected to finish around 2028-03-31.

How long any one person takes part can differ from the study length. The study team can tell you what the schedule looks like in practice.

From the trial registry
  • outcomesModule.primaryOutcomes[].timeFrame
  • statusModule.completionDateStruct.date
How many people are taking part?

The study aims to enrol about 20,000 people.

From the trial registry
  • designModule.enrollmentInfo.count
Where is this happening?

This study lists one location: Ottawa, Ontario, Canada.

Sites can open and close during a study, so confirm with the team before travelling.

From the trial registry
  • trial_locations

About This Trial

Extreme heat events pose a significant health threat in Canada, as demonstrated by the 2021 heat wave that claimed over 600 lives in Western Canada. Most heat-related deaths occur indoors and are preventable. Primary care providers (PCPs), who serve 88% of Canadians, are uniquely positioned to identify and support at-risk individuals. Heat Smart, in alignment with Heat Alert and Response Systems (HARS), aims to bridge the gap between primary care and public health to enhance community resilience and reduce health inequities related to extreme heat events. This randomized control trial in Eastern Ontario will examine whether patients receiving tailored digital health messages from their family physician or nurse practitioner change their behaviour to protect themselves from extreme heat-related illness. The Heat Smart study will: * Assess risk: Analyze electronic medical records and patient surveys to identify vulnerable individuals. * Deliver tailored messages: Send personalized digital guidance via e-mail or text, offering heat safety advice and local resource information in English and French. * Issue early warning alerts: Notify at-risk patients of upcoming heat events, prompting action. * Evaluate impact: Use surveys and health data to measure effectiveness in reducing heat-related health impacts. Short-term outcomes include increased awareness and preparedness among patients about heat-related health risks. Long-term goals involve scaling the intervention across Canada to reduce heat-related illnesses, enhance social connectedness, and decrease healthcare utilization.

Think this trial might be right for you?

Complete a quick intake form and we will match you with this and other relevant trials based on your medical profile.

See if this trial could fit you

This page is for informational purposes only and does not constitute medical advice. Clinical trial eligibility can only be determined by the trial site after proper screening. Trial information is sourced from ClinicalTrials.gov and may not reflect the most current status. Always consult your healthcare provider before making decisions about clinical trial participation.